secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001477932-25-001063
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.02, 5.03, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab creates Series Z Preferred with 5B votes to facilitate Reverse Stock Split
--------------------------------------------------------------------------------

- Created one share of Series Z Preferred Stock with 5,000,000,000 votes, solely on Reverse Stock Split matter.
- Issued to director Muhammad Azrul bin Abdul Hamid on Feb 10, 2025, exempt under Section 4(a)(2).
- Series Z will vote proportionally to common shares, increasing total votes but not affecting percentage for/against.
- Purpose is to ensure passage of Reverse Stock Split at upcoming Special Meeting.
- Share may be cancelled by Board or automatically upon shareholder approval of Reverse Split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225001063/0001477932-25-001063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225001063/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-001063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer